Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.

Schwartz will be stepping into an agency that has been battered by growing distrust, layoffs and the ever-looming presence of Kennedy, a longtime vaccine skeptic. “Erica Schwartz has a tough road ...

The pharma and biotech industries are constantly in flux. Every year, pharma professionals converge on a number of large ...

It’s been a record year so far for biotech bankruptcies. As of October, 28 biotech companies have gone bust compared to 20 last year and just nine in 2021. A number of factors have contributed to the ...

Dr. John Tsai grabbed the reins of global R&D this year with a clear mandate: extend Daiichi’s oncology momentum beyond its ...

The Danish biotech sharpened its global vaccine ambitions by tapping Tarja Stenvall, a Big Pharma vet, to take the helm.

The error points to a big question for pharma as AI gains autonomy and high-profile failures sharpen safety concerns: What ...

Nimbus Therapeutics’ head of R&D dishes on what’s next in AI-enabled drug discovery, years after Takeda completed its ...

Basecamp Research just netted $140 million in a series C fundraising round that valued the company at $800 million, according ...

Roche announced it's building autonomous AI-powered labs; how a clinical hold on an epilepsy trial could impact Biohaven ...

Companies including GSK, Merck, Roche and Sanofi are pushing new approaches in cancer and inflammatory diseases.

Patients in psychedelic trials often know if they’re taking the study drug or a placebo. But trial design changes could ...